Astellas Pharma Europe Ltd. and Theravance received marketing authorization from the European Commission for Vibativ (telavancin hydrochloride). Vibativ was discovered by Theravance and is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). The marketing authorization is for the treatment of adults with nosocomial pneumo...